GUJTHEM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 37/100 — Quality 44 · Valuation 18 · Momentum 50
| Share price | ₹363.95 |
| Market cap | ₹4,137 Cr |
| P/E ratio | 88.5 |
| P/B ratio | 14.3 |
| ROCE | 15.3% |
| Dividend yield | 0.18% |
| Book value | ₹26.41 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹166 Cr | ₹47 Cr | 37.8% |
| 2025 | ₹151 Cr | ₹49 Cr | 42.1% |
| 2024 | ₹170 Cr | ₹59 Cr | 44.5% |
| 2023 | ₹148 Cr | ₹58 Cr | 49.0% |
| 2022 | — | — | — |
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India and Japan. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.